Ignite Creation Date:
2024-05-05 @ 10:31 PM
Last Modification Date:
2024-10-26 @ 10:20 AM
Study NCT ID:
NCT01124734
Status:
COMPLETED
Last Update Posted:
2019-02-12
First Post:
2010-03-04
Brief Title:
High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
Sponsor:
Milton S Hershey Medical Center
Organization:
Milton S Hershey Medical Center
Study Overview
Official Title:
Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators have observed that many patients who had received high dose Interleukin-2 IL2 and failed to respond to it but who then go immediately to temozolomide seemed to enjoy extremely good responses which seem better quality and longer duration than typically observed for temozolomide alone To date the investigators have observed 5 sequentially treated patients with metastatic melanoma who had failed high dose IL-2 but who then went on to receive immediate temozolomide Two of these patients had complete responses and 3 had very strong partial response In a recent phase II study of extended low dose temozolomide alone given in the same manner as the post IL-2 patients noted above the response rate was 125 and all of these were partial responses only The responses that the investigators observed were at a much higher rate of response as well as much better quality than expected for temozolomide The responses were also better than those observed when temozolomide was given first and then followed by high dose IL-2 The investigators concluded that perhaps the major benefit the investigators observed was a result of the prior high dose IL-2 therapy modulated by the temozolomide and that the sequence of treatment was clearly crucial for this response
Detailed Description:
Metastatic malignant melanoma remains a disease with a very poor prognosis and median survival duration of less than one year Durable remissions with conventional therapy are rare and therefore clinical trials remain a primary treatment modality for metastatic disease There are 2 currently FDA-approved therapies for metastatic melanoma Chemotherapy with single agent parenteral dacarbazine or its oral pro-drug temozolomide are capable of producing responses in 65 to 20 of patients These responses are usually minor to partial at best and are not durable Combination with other chemotherapeutic drugs has not been successful The immune system also seems to play a role in malignant melanoma High dose Interferon therapy is the current standard therapy for the adjuvant treatment of stage IIB IIC and III melanoma after surgical resection in which it has shown to result in modest improvements in disease free survival and overall survival In metastatic disease various immunologic approaches have been employed as well High dose IL-2 can produce a response rate of about 10-15 in patients with metastatic melanoma About 5-10 of responses are complete and some of these complete responses are durable so that the lucky few patients who have a durable complete response are for all intents and purposes cured Attempts to combine chemotherapy with immunotherapy although improving response rates has not impacted survival as summarized in recent meta-analysis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None